Google ’s AI Bested Doctors in Detecting Breast Cancer in Mammograms

While there has been controversy over when and how often women should be screened for breast cancer using mammograms, studies consistently show that screening can lead to earlier detection of the disease, when it’s more treatable. So improving how effectively mammograms can detect abnormal growths that could be cancerous is a priority in the field. AI could play a role in accomplishing that—computer-based machine learning might help doctors to read mammograms more accurately. In a study published Jan. 1 in Nature, researchers from Google Health, and from universities in the U.S. and U.K., report on an AI model that reads mammograms with fewer false positives and false negatives than human experts. The algorithm, based on mammograms taken from more than 76,000 women in the U.K. and more than 15,000 in the U.S., reduced false positive rates by nearly 6% in the U.S., where women are screened every one to two years, and by 1.2% in the U.K., where women are screened every three years. The AI model also lowered false negatives by more than 9% in the U.S. and by nearly 3% in the U.K. “Reading mammograms is the perfect problem for machine learning and AI,” says Dr. Mozziyar Etemadi, research assistant professor of anesthesiology and biomedical engineering at Northwestern University and one of the paper’s co-authors. “AI excels when it has to do the same task over and over again, and has to find the one thing that might appear one time out of 10,00...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Artifical Intelligence Breast Cancer embargoed study MSFTAI2019 Source Type: news

Related Links:

Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
This study is the first to provide a direct link between this inflammation and plaque development - by way of IFITM3. Scientists know that the production of IFITM3 starts in response to activation of the immune system by invading viruses and bacteria. These observations, combined with the new findings that IFITM3 directly contributes to plaque formation, suggest that viral and bacterial infections could increase the risk of Alzheimer's disease development. Indeed, researchers found that the level of IFITM3 in human brain samples correlated with levels of certain viral infections as well as with gamma-secretase activ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
The objective of this study was to conduct a systematic review and dose-response meta-analysis of physical activity and mortality in people with selected non-communicable diseases (NCDs). We aimed to define the dose-response relationship between post-diagnosis physical activity and mortality rates for nine NCDs with a high global burden of disease, including low back pain, type 2 diabetes (T2D), osteoarthritis, depressive disorder, chronic obstructive pulmonary disease (COPD), breast cancer, lung cancer, stroke, and ischemic heart disease (IHD). In total, 28 studies were included in the meta-analysis: 12 for breast ...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
This study aims to investigate the relationship between post-diagnosis physical activity and mortality in patients with selected noncommunicable diseases, including breast cancer, lung cancer, type 2 diabetes,...
Source: International Journal of Behavioral Nutrition and Physical Activity - Category: Nutrition Authors: Tags: Review Source Type: research
Basel, 06 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion131 study, evaluating Tecentriq® (atezolizumab) in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-fr ee survival (PFS) for the initial (first-line) treatment of people with metastatic triple-negative breast cancer (TNBC), in the PD-L1-positive population. The data for the secondary endpoint of overall survival (OS) showed a negative trend, however, the study was not powered for the secondary endpoi...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
CONCLUSIONS: Long non-coding RNA CDKN2B-AS1 likely serves as a promising therapeutic target or prognosis biomarker in multiple human diseases. PMID: 32767927 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research
Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.“Ovarian cancer remains one of the most aggressive cancers a...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Basel, 18 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion031 study, evaluating Tecentriq® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel; followed by doxorubicin and cyclophosphamide) in comparison to placebo plus chem otherapy (including Abraxane), met its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in pathological complete response (pCR) for the treatment of people with early triple-negative breast cancer (TNBC), regardless of PD-L1 expression.“Tripl...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
umar B Kunnumakkara According to the World Health Organization (WHO), cancer is the second-highest cause of mortality in the world, and it kills nearly 9.6 million people annually. Besides the fatality of the disease, poor prognosis, cost of conventional therapies, and associated side-effects add more burden to patients, post-diagnosis. Therefore, the search for alternatives for the treatment of cancer that are safe, multi-targeted, effective, and cost-effective has compelled us to go back to ancient systems of medicine. Natural herbs and plant formulations are laden with a variety of phytochemicals. One such compound ...
Source: Molecules - Category: Chemistry Authors: Tags: Review Source Type: research
This study provides comprehensive information about the structures, formation, and types of the oxysterols even when involved in certain disease states, focusing on their effects on metabolism and linkages with these diseases. The role of specific oxysterols as mediators in various disorders, such as degenerative (age-related) and cancer-related disorders, have now become clearer. Oxysterol levels may be employed as suitable markers for the diagnosis of specific diseases or in predicting the incidence rate of diseases, such as diabetes mellitus, Alzheimer's disease, multiple sclerosis, osteoporosis, lung cancer, breast can...
Source: Current Medicinal Chemistry - Category: Chemistry Authors: Tags: Curr Med Chem Source Type: research
More News: Anesthesia | Anesthesiology | Biomedical Engineering | Breast Cancer | Cancer | Cancer & Oncology | Computers | CT Scan | Databases & Libraries | Diabetes | Endocrinology | Health | Health Management | Hospitals | Learning | Lung Cancer | Mammography | PET Scan | Radiology | Statistics | Study | Universities | Universities & Medical Training | Vitamin A | Women